693 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
This $26 Billion Company Is the Market's Most Overpriced Biotech Stock https://www.fool.com/investing/2017/04/20/this-26-billion-company-is-the-markets-most-overpr.aspx?source=iedfolrf0000001 Apr 20, 2017 - Nearly 90% of this biotech's sales could be at risk within the next two years.
Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around? https://www.fool.com/investing/2017/04/25/will-low-pricing-for-siliq-be-enough-to-help-valea.aspx?source=iedfolrf0000001 Apr 25, 2017 - Valeant is undercutting Novartis and Lilly with its pricing of psoriasis drug Siliq. How much will the strategy help?
Why Incyte Corporation Stock Is Plunging Today https://www.fool.com/investing/2017/04/17/why-incyte-corporation-stock-is-plunging-today.aspx?source=iedfolrf0000001 Apr 17, 2017 - Shares of Incyte and Eli Lilly are reeling following the FDA's rejection of their once-daily rheumatoid arthritis pill.
1 Great Biotech Stock You Have Never Heard Of https://www.fool.com/investing/2017/09/29/1-great-biotech-stock-you-have-never-heard-of.aspx?source=iedfolrf0000001 Sep 29, 2017 - Big pharma companies have thrown hundreds of millions of dollars at this small biotech. Should retail investors follow suit?
Bristol-Myers Inks Another Immuno-Oncology Drug Deal http://www.zacks.com/stock/news/188393/bristol-myers-inks-another-immuno-oncology-drug-deal?cid=CS-ZC-FT-188393 Aug 31, 2015 - Bristol-Myers Squibb Company (BMY) announced that it has entered into a research collaboration and license agreement with QIMR Berghofer Medical Research Institute.
Exelixis' Cancer Drug Gets Breakthrough Therapy Status http://www.zacks.com/stock/news/187683/exelixis-cancer-drug-gets-breakthrough-therapy-status?cid=CS-ZC-FT-187683 Aug 25, 2015 - Exelixis, Inc. (EXEL) announced that its oncology drug, Cometriq has received Breakthrough Therapy designation from the FDA.
Oncolytics' Reolysin Phase II Lung Cancer Study Enrolled http://www.zacks.com/stock/news/188033/oncolytics-reolysin-phase-ii-lung-cancer-study-enrolled?cid=CS-ZC-FT-188033 Aug 27, 2015 - Oncolytics Biotech (ONCY) completed enrolling patients in a phase II study on Reolysin for the treatment of non-small cell lung cancer.
Vital Therapies Hit By Disappointing Data on Liver Drug http://www.zacks.com/stock/news/187492/vital-therapies-hit-by-disappointing-data-on-liver-drug?cid=CS-ZC-FT-187492 Aug 24, 2015 - Vital Therapies, Inc. (VTL) announced negative top-line data from the phase III VTI-208 study evaluating the ELAD System in patients with alcohol-induced liver decompensation.
3M Invests for Minority Stake in StrongArm Technologies http://www.zacks.com/stock/news/190601/3m-invests-for-minority-stake-in-strongarm-technologies?cid=CS-ZC-FT-190601 Sep 18, 2015 - 3M Safety and Graphics Business Group, a part of 3M Company (MMM), recently announced a minority equity investment in StrongArm Technologies Inc., - a company that designs innovative safety products.
Eli Lilly & Co. (LLY) John C. Lechleiter on Q1 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3968278-eli-lilly-and-co-lly-john-c-lechleiter-q1-2016-results-earnings-call-transcript?source=feed_all_articles Apr 26, 2016 - Eli Lilly & Co. (NYSE:LLY)Q1 2016 Earnings CallApril 26, 2016 9:00 am ETExecutivesJohn C. Lechleiter - Chairman, President & Chief Executive OfficerPhilip Johnson - Vice President, Investor Relations,

Pages: 123456789...70

<<<Page 4>